Get the Stockscreener App
25.92
0.12%
0.03
Parabilis Medicines Inc stock is traded at $25.92, with a volume of 287.47K.
It is up +0.12% in the last 24 hours and down -27.44% over the past month.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
See More
Previous Close:
$25.89
Open:
$25.76
24h Volume:
287.47K
Relative Volume:
0.29
Market Cap:
$3.20B
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-7.73%
1M Performance:
-27.44%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$25.10
$26.43
1-Week Range:
$25.73
$29.50
52-Week Range:
$24.51
$42.48
Parabilis Medicines Inc Stock (PBLS) Company Profile
Name
Parabilis Medicines Inc
Sector
Industry
Phone
-
Address
-
Compare PBLS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
25.92 | 3.20B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Parabilis Medicines Inc Stock (PBLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-26 | Initiated | BofA Securities | Buy |
| Jul-06-26 | Initiated | Evercore ISI | Outperform |
| Jul-06-26 | Initiated | Guggenheim | Buy |
| Jul-06-26 | Initiated | Leerink Partners | Outperform |
Parabilis Medicines Inc Stock (PBLS) Latest News
Parabilis Medicines, Inc. (PBLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Parabilis Medicines (Nasdaq:PBLS)Stock Analysis - Simply Wall Street
48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC - marketbeat.com
Parabilis Medicines (PBLS) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance
ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - marketbeat.com
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC - MarketBeat
venBio Partners LLC Takes $144.15 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Parabilis appoints Craig Tendler to its Board and Science & Technology Committee - TradingView
Parabilis Medicines adds former J&J oncology executive to board By Investing.com - Investing.com Canada
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors - Yahoo Finance
ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines Price Insights - YCharts
Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat
Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Biotech’s reverse merger renaissance poised to continue - Endpoints News
Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - kalkine.ca
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - kalkine.com.au
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com South Africa
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Canada
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Australia
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com India
Parabilis Medicines Reports Second Quarter 2026 Financial Results And Provides Business Updates - TradingView
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com UK
Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000 - marketscreener.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Parabilis Medicines Advances Zolucatetide Toward Phase 3 in Desmoid Tumors, Announces Regeneron Collaboration and $1.1 Billion Cash Position - Quiver Quantitative
Parabilis Medicines: Q2 Earnings Snapshot - marketscreener.com
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Parabilis Medicines Inc Stock (PBLS) Financials Data
There is no financial data for Parabilis Medicines Inc (PBLS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Parabilis Medicines Inc Stock (PBLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 22 '26 |
Buy |
29.77 |
47,250 |
1,406,632 |
26,529,686 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 21 '26 |
Buy |
29.25 |
65,923 |
1,928,032 |
26,482,436 |
| SEBULSKY ALAN | Director |
Jun 15 '26 |
Buy |
26.49 |
9,065 |
240,135 |
30,000 |
| SEBULSKY ALAN | Director |
Jun 12 '26 |
Buy |
27.67 |
8,435 |
233,393 |
20,935 |
| Levy Guy | 10% Owner |
Jun 11 '26 |
Buy |
20.00 |
500,000 |
10,000,000 |
1,027,000 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
20.00 |
21,188,750 |
423,775,000 |
26,285,093 |
| SEBULSKY ALAN | Director |
Jun 11 '26 |
Buy |
20.00 |
12,500 |
250,000 |
12,500 |
0.07%
2.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):